Top

Published in:

Open Access 01-12-2014 | Research

Anti-IGF-1R monoclonal antibody inhibits the carcinogenicity activity of acquired trastuzumab-resistant SKOV3

Authors: Wei Wang, Yan Zhang, Ming Lv, Jiannan Feng, Hui Peng, Jing Geng, Zhou Lin, Tingting Zhou, Xinying Li, Beifen Shen, Yuanfang Ma, Chunxia Qiao

Published in: Journal of Ovarian Research | Issue 1/2014

Abstract

Background

Antibody resistance, not only de novo but also acquired cases, usually exists and is related with lower survival rate and high risk of recurrence. Reversing the resistance often results in better clinical therapeutic effect. Previously, we established a trastuzumab-resistant ovarian cancer cell line, named as SKOV3-T, with lower HER2 and induced higher IGF-1R expression level to keep cell survival.

Methods

IGF-1R was identified important for SKOV3-T growth. Then, a novel anti-IGF-1R monoclonal antibody, named as LMAb1, was used to inhibit SKOV3-T in cell growth/proliferation, migration, clone formation and in vivo carcinogenicity.

Results

In both in vitro and in vivo assays, LMAb1 showed effective anti-tumor function, especially when being used in combination with trastuzumab, which was beneficial to longer survival time of mice as well as smaller tumor. It was also confirmed preliminarily that the mechanism of antibody might be to inhibit the activation of IGF-1R and downstream MAPK, AKT pathway transduction.

Conclusion

We achieved satisfactory anti-tumor activity using trastuzumab plus LMAb1 in trastuzumab-resistant ovarian cancer model. In similar cases, not only acquired but also de novo, good curative effect might be achieved using combined antibody therapy strategies.

Available only for authorised users

Raval RR, Sharabi AB, Walker AJ, Drake CG, Sharma P: Tumor immunology and cancer immunotherapy: summary of the 2013 SITC primer. J Immunother Cancer 2014, 2: 14. 10.1186/2051-1426-2-14PubMedCentralCrossRefPubMed

Slichenmyer WJ, Fry DW: Anticancer therapy targeting the erbB family of receptor tyrosine kinases. Semin Oncol 2001, 28: 67–79. 10.1016/S0093-7754(01)90284-2CrossRefPubMed

Schmidt M, Lewark B, Kohlschmidt N, Glawatz C, Steiner E, Tanner B, Pilch H, Weikel W, Kolbl H, Lehr HA: Long-term prognostic significance of HER-2/neu in untreated node-negative breast cancer depends on the method of testing. Breast Cancer Res 2005, 7: R256-R266. 10.1186/bcr991PubMedCentralCrossRefPubMed

Ross JS, Fletcher JA: The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy. Oncologist 1998, 3: 237–252.PubMed

Ladjemi MZ, Jacot W, Chardes T, Pelegrin A, Navarro-Teulon I: Anti-HER2 vaccines: new prospects for breast cancer therapy. Cancer Immunol Immunother 2010, 59: 1295–1312. 10.1007/s00262-010-0869-2PubMedCentralCrossRefPubMed

Hynes NE, Stern DF: The biology of erbB-2/neu/HER-2 and its role in cancer. Biochim Biophys Acta 1994, 1198: 165–184.PubMed

Clynes RA, Towers TL, Presta LG, Ravetch JV: Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med 2000, 6: 443–446. 10.1038/74704CrossRefPubMed

Gennari R, Menard S, Fagnoni F, Ponchio L, Scelsi M, Tagliabue E, Castiglioni F, Villani L, Magalotti C, Gibelli N, Oliviero B, Ballardini B, Da Prada G, Zambelli A, Costa A: Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2. Clin Cancer Res 2004, 10: 5650–5655. 10.1158/1078-0432.CCR-04-0225CrossRefPubMed

Arnould L, Gelly M, Penault-Llorca F, Benoit L, Bonnetain F, Migeon C, Cabaret V, Fermeaux V, Bertheau P, Garnier J, Jeannin JF, Coudert B: Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism? Br J Cancer 2006, 94: 259–267. 10.1038/sj.bjc.6602930PubMedCentralCrossRefPubMed

10.

Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, Gianni L, Baselga J, Bell R, Jackisch C, Cameron D, Dowsett M, Barrios CH, Steger G, Huang CS, Andersson M, Inbar M, Lichinitser M, Lang I, Nitz U, Iwata H, Thomssen C, Lohrisch C, Suter TM, Ruschoff J, Suto T, Greatorex V, Ward C, Straehle C, McFadden E, Dolci MS, Gelber RD: Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005, 353: 1659–1672. 10.1056/NEJMoa052306CrossRefPubMed

11.

Mullen P, Cameron DA, Hasmann M, Smyth JF, Langdon SP: Sensitivity to pertuzumab (2C4) in ovarian cancer models: cross-talk with estrogen receptor signaling. Mol Cancer Ther 2007, 6: 93–100. 10.1158/1535-7163.MCT-06-0401CrossRefPubMed

12.

Agus DB, Akita RW, Fox WD, Lewis GD, Higgins B, Pisacane PI, Lofgren JA, Tindell C, Evans DP, Maiese K, Scher HI, Sliwkowski MX: Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell 2002, 2: 127–137. 10.1016/S1535-6108(02)00097-1CrossRefPubMed

13.

Jackson JG, St Clair P, Sliwkowski MX, Brattain MG: Blockade of epidermal growth factor- or heregulin-dependent ErbB2 activation with the anti-ErbB2 monoclonal antibody 2C4 has divergent downstream signaling and growth effects. Cancer Res 2004, 64: 2601–2609. 10.1158/0008-5472.CAN-03-3106CrossRefPubMed

14.

Nahta R, Hung MC, Esteva FJ: The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells. Cancer Res 2004, 64: 2343–2346. 10.1158/0008-5472.CAN-03-3856CrossRefPubMed

15.

Takai N, Jain A, Kawamata N, Popoviciu LM, Said JW, Whittaker S, Miyakawa I, Agus DB, Koeffler HP: 2C4, a monoclonal antibody against HER2, disrupts the HER kinase signaling pathway and inhibits ovarian carcinoma cell growth. Cancer 2005, 104: 2701–2708. 10.1002/cncr.21533CrossRefPubMed

16.

Teicher BA, Doroshow JH: The promise of antibody-drug conjugates. N Engl J Med 2012, 367: 1847–1848. 10.1056/NEJMe1211736CrossRefPubMed

17.

Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, Pegram M, Oh DY, Dieras V, Guardino E, Fang L, Lu MW, Olsen S, Blackwell K: Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 2012, 367: 1783–1791. 10.1056/NEJMoa1209124CrossRefPubMed

18.

Tagliabue E, Campiglio M, Pupa SM, Menard S, Balsari A: Activity and resistance of trastuzumab according to different clinical settings. Cancer Treat Rev 2012, 38: 212–217. 10.1016/j.ctrv.2011.06.002CrossRefPubMed

19.

Piccart M: Circumventing de novo and acquired resistance to trastuzumab: new hope for the care of ErbB2-positive breast cancer. Clin Breast Cancer 2008,8(Suppl 3):S100-S113. 10.3816/CBC.2008.s.006CrossRefPubMed

20.

Liebisch P, Eppinger S, Schopflin C, Stehle G, Munzert G, Dohner H, Schmid M: CD44v6, a target for novel antibody treatment approaches, is frequently expressed in multiple myeloma and associated with deletion of chromosome arm 13q. Haematologica 2005, 90: 489–493.PubMed

21.

Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, Harousseau JL, Ben-Yehuda D, Lonial S, Goldschmidt H, Reece D, San-Miguel JF, Blade J, Boccadoro M, Cavenagh J, Dalton WS, Boral AL, Esseltine DL, Porter JB, Schenkein D, Anderson KC: Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005, 352: 2487–2498. 10.1056/NEJMoa043445CrossRefPubMed

22.

Saltz LB, Meropol NJ, Loehrer PJ Sr, Needle MN, Kopit J, Mayer RJ: Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004, 22: 1201–1208. 10.1200/JCO.2004.10.182CrossRefPubMed

23.

Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, Chau I, Van Cutsem E: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004, 351: 337–345. 10.1056/NEJMoa033025CrossRefPubMed

24.

Lenz HJ, Van Cutsem E, Khambata-Ford S, Mayer RJ, Gold P, Stella P, Mirtsching B, Cohn AL, Pippas AW, Azarnia N, Tsuchihashi Z, Mauro DJ, Rowinsky EK: Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines. J Clin Oncol 2006, 24: 4914–4921. 10.1200/JCO.2006.06.7595CrossRefPubMed

25.

Van Cutsem E, Peeters M, Siena S, Humblet Y, Hendlisz A, Neyns B, Canon JL, Van Laethem JL, Maurel J, Richardson G, Wolf M, Amado RG: Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 2007, 25: 1658–1664. 10.1200/JCO.2006.08.1620CrossRefPubMed

26.

Allegra CJ, Jessup JM, Somerfield MR, Hamilton SR, Hammond EH, Hayes DF, McAllister PK, Morton RF, Schilsky RL: American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol 2009, 27: 2091–2096. 10.1200/JCO.2009.21.9170CrossRefPubMed

27.

Morton RF, Hammond EH: ASCO provisional clinical opinion: KRAS, cetuximab, and panitumumab-clinical implications in colorectal cancer. J Oncol Pract 2009, 5: 71–72. 10.1200/JOP.0924603PubMedCentralCrossRefPubMed

28.

Sartore-Bianchi A, Di Nicolantonio F, Nichelatti M, Molinari F, De Dosso S, Saletti P, Martini M, Cipani T, Marrapese G, Mazzucchelli L, Lamba S, Veronese S, Frattini M, Bardelli A, Siena S: Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer. PLoS One 2009, 4: e7287. 10.1371/journal.pone.0007287PubMedCentralCrossRefPubMed

29.

Di Fiore F, Blanchard F, Charbonnier F, Le Pessot F, Lamy A, Galais MP, Bastit L, Killian A, Sesboue R, Tuech JJ, Queuniet AM, Paillot B, Sabourin JC, Michot F, Michel P, Frebourg T: Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy. Br J Cancer 2007, 96: 1166–1169. 10.1038/sj.bjc.6603685PubMedCentralCrossRefPubMed

30.

De Roock W, Piessevaux H, De Schutter J, Janssens M, De Hertogh G, Personeni N, Biesmans B, Van Laethem JL, Peeters M, Humblet Y, Van Cutsem E, Tejpar S: KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann Oncol 2008, 19: 508–515. 10.1093/annonc/mdm496CrossRefPubMed

31.

Karapetis CS, Khambata-Ford S, Jonker DJ, O’Callaghan CJ, Tu D, Tebbutt NC, Simes RJ, Chalchal H, Shapiro JD, Robitaille S, Price TJ, Shepherd L, Au HJ, Langer C, Moore MJ, Zalcberg JR: K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008, 359: 1757–1765. 10.1056/NEJMoa0804385CrossRefPubMed

32.

Lievre A, Bachet JB, Boige V, Cayre A, Le Corre D, Buc E, Ychou M, Bouche O, Landi B, Louvet C, Andre T, Bibeau F, Diebold MD, Rougier P, Ducreux M, Tomasic G, Emile JF, Penault-Llorca F, Laurent-Puig P: KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 2008, 26: 374–379. 10.1200/JCO.2007.12.5906CrossRefPubMed

33.

Freeman DJ, Juan T, Reiner M, Hecht JR, Meropol NJ, Berlin J, Mitchell E, Sarosi I, Radinsky R, Amado RG: Association of K-ras mutational status and clinical outcomes in patients with metastatic colorectal cancer receiving panitumumab alone. Clin Colorectal Cancer 2008, 7: 184–190. 10.3816/CCC.2008.n.024CrossRefPubMed

34.

Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, Juan T, Sikorski R, Suggs S, Radinsky R, Patterson SD, Chang DD: Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008, 26: 1626–1634. 10.1200/JCO.2007.14.7116CrossRefPubMed

35.

Perkins G, Lievre A, Ramacci C, Meatchi T, de Reynies A, Emile JF, Boige V, Tomasic G, Bachet JB, Bibeau F, Bouche O, Penault-Llorca F, Merlin JL, Laurent-Puig P: Additional value of EGFR downstream signaling phosphoprotein expression to KRAS status for response to anti-EGFR antibodies in colorectal cancer. Int J Cancer 2010, 127: 1321–1331. 10.1002/ijc.25152CrossRefPubMed

36.

Lievre A, Bachet JB, Le Corre D, Boige V, Landi B, Emile JF, Cote JF, Tomasic G, Penna C, Ducreux M, Rougier P, Penault-Llorca F, Laurent-Puig P: KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 2006, 66: 3992–3995. 10.1158/0008-5472.CAN-06-0191CrossRefPubMed

37.

Saridaki Z, Tzardi M, Papadaki C, Sfakianaki M, Pega F, Kalikaki A, Tsakalaki E, Trypaki M, Messaritakis I, Stathopoulos E, Mavroudis D, Georgoulias V, Souglakos J: Impact of KRAS, BRAF, PIK3CA mutations, PTEN, AREG, EREG expression and skin rash in >/= 2 line cetuximab-based therapy of colorectal cancer patients. PLoS One 2011, 6: e15980. 10.1371/journal.pone.0015980PubMedCentralCrossRefPubMed

38.

Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, Pienkowski T, Jagiello-Gruszfeld A, Crown J, Chan A, Kaufman B, Skarlos D, Campone M, Davidson N, Berger M, Oliva C, Rubin SD, Stein S, Cameron D: Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006, 355: 2733–2743. 10.1056/NEJMoa064320CrossRefPubMed

39.

von Minckwitz G, du Bois A, Schmidt M, Maass N, Cufer T, de Jongh FE, Maartense E, Zielinski C, Kaufmann M, Bauer W, Baumann KH, Clemens MR, Duerr R, Uleer C, Andersson M, Stein RC, Nekljudova V, Loibl S: Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03–05 study. J Clin Oncol 2009, 27: 1999–2006. 10.1200/JCO.2008.19.6618CrossRefPubMed

40.

Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004, 350: 2335–2342. 10.1056/NEJMoa032691CrossRefPubMed

41.

Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH: Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006, 355: 2542–2550. 10.1056/NEJMoa061884CrossRefPubMed

42.

Valachis A, Polyzos NP, Patsopoulos NA, Georgoulias V, Mavroudis D, Mauri D: Bevacizumab in metastatic breast cancer: a meta-analysis of randomized controlled trials. Breast Cancer Res Treat 2010, 122: 1–7. 10.1007/s10549-009-0727-0CrossRefPubMed

43.

Jia Y, Zhang Y, Qiao C, Liu G, Zhao Q, Zhou T, Chen G, Li Y, Feng J, Zhang Q, Peng H: IGF-1R and ErbB3/HER3 contribute to enhanced proliferation and carcinogenesis in trastuzumab-resistant ovarian cancer model. Biochem Biophys Res Commun 2013, 436: 740–745. 10.1016/j.bbrc.2013.06.030CrossRefPubMed

44.

Yang T, Burrows C, Park JH: Development of a doxycycline-inducible lentiviral plasmid with an instant regulatory feature. Plasmid 2014, 72: 29–35. 10.1016/j.plasmid.2014.04.001CrossRefPubMed

45.

Pollak M: Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer 2008, 8: 915–928. 10.1038/nrc2536CrossRefPubMed

46.

Baserga R: The IGF-I receptor in cancer research. Exp Cell Res 1999, 253: 1–6. 10.1006/excr.1999.4667CrossRefPubMed

47.

Pollak MN, Schernhammer ES, Hankinson SE: Insulin-like growth factors and neoplasia. Nat Rev Cancer 2004, 4: 505–518. 10.1038/nrc1387CrossRefPubMed

48.

Clemmons DR: Involvement of insulin-like growth factor-I in the control of glucose homeostasis. Curr Opin Pharmacol 2006, 6: 620–625. 10.1016/j.coph.2006.08.006CrossRefPubMed

49.

LeRoith D, Yakar S: Mechanisms of disease: metabolic effects of growth hormone and insulin-like growth factor 1. Nat Clin Pract Endocrinol Metab 2007, 3: 302–310. 10.1038/ncpendmet0427CrossRefPubMed

50.

Cullen KJ, Yee D, Sly WS, Perdue J, Hampton B, Lippman ME, Rosen N: Insulin-like growth factor receptor expression and function in human breast cancer. Cancer Res 1990, 50: 48–53.PubMed

51.

Gooch JL, Van Den Berg CL, Yee D: Insulin-like growth factor (IGF)-I rescues breast cancer cells from chemotherapy-induced cell death–proliferative and anti-apoptotic effects. Breast Cancer Res Treat 1999, 56: 1–10. 10.1023/A:1006208721167CrossRefPubMed

52.

Lee AV, Yee D: Insulin-like growth factors and breast cancer. Biomed Pharmacother 1995, 49: 415–421. 10.1016/0753-3322(96)82678-3CrossRefPubMed

53.

Peyrat JP, Bonneterre J: Type 1 IGF receptor in human breast diseases. Breast Cancer Res Treat 1992, 22: 59–67. 10.1007/BF01833334CrossRefPubMed

54.

Hassan AB, Macaulay VM: The insulin-like growth factor system as a therapeutic target in colorectal cancer. Ann Oncol 2002, 13: 349–356. 10.1093/annonc/mdf096CrossRefPubMed

55.

Wu Y, Yakar S, Zhao L, Hennighausen L, LeRoith D: Circulating insulin-like growth factor-I levels regulate colon cancer growth and metastasis. Cancer Res 2002, 62: 1030–1035.PubMed

56.

Nickerson T, Chang F, Lorimer D, Smeekens SP, Sawyers CL, Pollak M: In vivo progression of LAPC-9 and LNCaP prostate cancer models to androgen independence is associated with increased expression of insulin-like growth factor I (IGF-I) and IGF-I receptor (IGF-IR). Cancer Res 2001, 61: 6276–6280.PubMed

57.

Ge NL, Rudikoff S: Insulin-like growth factor I is a dual effector of multiple myeloma cell growth. Blood 2000, 96: 2856–2861.PubMed

58.

Gee JM, Robertson JF, Gutteridge E, Ellis IO, Pinder SE, Rubini M, Nicholson RI: Epidermal growth factor receptor/HER2/insulin-like growth factor receptor signalling and oestrogen receptor activity in clinical breast cancer. Endocr Relat Cancer 2005,12(Suppl 1):S99-S111. 10.1677/erc.1.01005CrossRefPubMed

59.

Villanueva J, Vultur A, Lee JT, Somasundaram R, Fukunaga-Kalabis M, Cipolla AK, Wubbenhorst B, Xu X, Gimotty PA, Kee D, Santiago-Walker AE, Letrero R, D’Andrea K, Pushparajan A, Hayden JE, Brown KD, Laquerre S, McArthur GA, Sosman JA, Nathanson KL, Herlyn M: Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell 2010, 18: 683–695. 10.1016/j.ccr.2010.11.023PubMedCentralCrossRefPubMed

60.

Shin DH, Min HY, El-Naggar AK, Lippman SM, Glisson B, Lee HY: Akt/mTOR counteract the antitumor activities of cixutumumab, an anti-insulin-like growth factor I receptor monoclonal antibody. Mol Cancer Ther 2011, 10: 2437–2448. 10.1158/1535-7163.MCT-11-0235PubMedCentralCrossRefPubMed

61.

Iravani S, Zhang HQ, Yuan ZQ, Cheng JQ, Karl RC, Jove R, Coppola D: Modification of insulin-like growth factor 1 receptor, c-Src, and Bcl-XL protein expression during the progression of Barrett’s neoplasia. Hum Pathol 2003, 34: 975–982. 10.1053/S0046-8177(03)00354-XCrossRefPubMed

62.

LeRoith D, Baserga R, Helman L, Roberts CT Jr: Insulin-like growth factors and cancer. Ann Intern Med 1995, 122: 54–59. 10.7326/0003-4819-122-1-199501010-00009CrossRefPubMed

63.

Berns EM, Klijn JG, van Staveren IL, Portengen H, Foekens JA: Sporadic amplification of the insulin-like growth factor 1 receptor gene in human breast tumors. Cancer Res 1992, 52: 1036–1039.PubMed

64.

De Souza AT, Hankins GR, Washington MK, Fine RL, Orton TC, Jirtle RL: Frequent loss of heterozygosity on 6q at the mannose 6-phosphate/insulin-like growth factor II receptor locus in human hepatocellular tumors. Oncogene 1995, 10: 1725–1729.PubMed

65.

Cui H, Cruz-Correa M, Giardiello FM, Hutcheon DF, Kafonek DR, Brandenburg S, Wu Y, He X, Powe NR, Feinberg AP: Loss of IGF2 imprinting: a potential marker of colorectal cancer risk. Science 2003, 299: 1753–1755. 10.1126/science.1080902CrossRefPubMed

66.

Kaneda A, Feinberg AP: Loss of imprinting of IGF2: a common epigenetic modifier of intestinal tumor risk. Cancer Res 2005, 65: 11236–11240. 10.1158/0008-5472.CAN-05-2959CrossRefPubMed

67.

Abou-Alfa GK, Capanu M, O’Reilly EM, Ma J, Chou JF, Gansukh B, Shia J, Kalin M, Katz S, Abad L, Reidy-Lagunes DL, Kelsen DP, Chen HX, Saltz LB: A phase II study of cixutumumab (IMC-A12, NSC742460) in advanced hepatocellular carcinoma. J Hepatol 2014, 60: 319–324. 10.1016/j.jhep.2013.09.008PubMedCentralCrossRefPubMed

68.

Attias-Geva Z, Bentov I, Ludwig DL, Fishman A, Bruchim I, Werner H: Insulin-like growth factor-I receptor (IGF-IR) targeting with monoclonal antibody cixutumumab (IMC-A12) inhibits IGF-I action in endometrial cancer cells. Eur J Cancer 2011, 47: 1717–1726. 10.1016/j.ejca.2011.02.019CrossRefPubMed

69.

Rowinsky EK, Youssoufian H, Tonra JR, Solomon P, Burtrum D, Ludwig DL: IMC-A12, a human IgG1 monoclonal antibody to the insulin-like growth factor I receptor. Clin Cancer Res 2007, 13: 5549s-5555s. 10.1158/1078-0432.CCR-07-1109CrossRefPubMed

70.

Chi KN, Gleave ME, Fazli L, Goldenberg SL, So A, Kollmannsberger C, Murray N, Tinker A, Pollak M: A phase II pharmacodynamic study of preoperative figitumumab in patients with localized prostate cancer. Clin Cancer Res 2012, 18: 3407–3413. 10.1158/1078-0432.CCR-12-0482CrossRefPubMed

71.

de Bono JS, Piulats JM, Pandha HS, Petrylak DP, Saad F, Aparicio LM, Sandhu SK, Fong P, Gillessen S, Hudes GR, Wang T, Scranton J, Pollak MN: Phase II randomized study of figitumumab plus docetaxel and docetaxel alone with crossover for metastatic castration-resistant prostate cancer. Clin Cancer Res 2014, 20: 1925–1934. 10.1158/1078-0432.CCR-13-1869CrossRefPubMed

72.

Gualberto A, Karp DD: Development of the monoclonal antibody figitumumab, targeting the insulin-like growth factor-1 receptor, for the treatment of patients with non-small-cell lung cancer. Clin Lung Cancer 2009, 10: 273–280. 10.3816/CLC.2009.n.038CrossRefPubMed

73.

Langer CJ, Novello S, Park K, Krzakowski M, Karp DD, Mok T, Benner RJ, Scranton JR, Olszanski AJ, Jassem J: Randomized, phase III trial of first-line figitumumab in combination with paclitaxel and carboplatin versus paclitaxel and carboplatin alone in patients with advanced non-small-cell lung cancer. J Clin Oncol 2014, 32: 2059–2066. 10.1200/JCO.2013.54.4932PubMedCentralCrossRefPubMed

74.

Schmitz S, Kaminsky-Forrett MC, Henry S, Zanetta S, Geoffrois L, Bompas E, Moxhon A, Mignion L, Guigay J, Knoops L, Hamoir M, Machiels JP: Phase II study of figitumumab in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: clinical activity and molecular response (GORTEC 2008–02). Ann Oncol 2012, 23: 2153–2161. 10.1093/annonc/mdr574CrossRefPubMed

75.

Atzori F, Tabernero J, Cervantes A, Prudkin L, Andreu J, Rodriguez-Braun E, Domingo A, Guijarro J, Gamez C, Rodon J, Di Cosimo S, Brown H, Clark J, Hardwick JS, Beckman RA, Hanley WD, Hsu K, Calvo E, Rosello S, Langdon RB, Baselga J: A phase I pharmacokinetic and pharmacodynamic study of dalotuzumab (MK-0646), an anti-insulin-like growth factor-1 receptor monoclonal antibody, in patients with advanced solid tumors. Clin Cancer Res 2011, 17: 6304–6312. 10.1158/1078-0432.CCR-10-3336CrossRefPubMed

76.

Ellis PM, Shepherd FA, Laurie SA, Goss GD, Olivo M, Powers J, Seymour L, Bradbury PA: NCIC CTG IND.190 phase I trial of dalotuzumab (MK-0646) in combination with cisplatin and etoposide in extensive-stage small-cell lung cancer. J Thorac Oncol 2014, 9: 410–413. 10.1097/JTO.0000000000000058CrossRefPubMed

77.

Scartozzi M, Bianconi M, Maccaroni E, Giampieri R, Berardi R, Cascinu S: Dalotuzumab, a recombinant humanized mAb targeted against IGFR1 for the treatment of cancer. Curr Opin Mol Ther 2010, 12: 361–371.PubMed

78.

Beltran PJ, Calzone FJ, Mitchell P, Chung YA, Cajulis E, Moody G, Belmontes B, Li CM, Vonderfecht S, Velculescu VE, Yang G, Qi J, Slamon DJ, Konecny GE: Ganitumab (AMG 479) inhibits IGF-II-dependent ovarian cancer growth and potentiates platinum-based chemotherapy. Clin Cancer Res 2014, 20: 2947–2958. 10.1158/1078-0432.CCR-13-3448PubMedCentralCrossRefPubMed

79.

Strosberg JR, Chan JA, Ryan DP, Meyerhardt JA, Fuchs CS, Abrams T, Regan E, Brady R, Weber J, Campos T, Kvols LK, Kulke MH: A multi-institutional, phase II open-label study of ganitumab (AMG 479) in advanced carcinoid and pancreatic neuroendocrine tumors. Endocr Relat Cancer 2013, 20: 383–390. 10.1530/ERC-12-0390PubMedCentralCrossRefPubMed

80.

Tap WD, Demetri G, Barnette P, Desai J, Kavan P, Tozer R, Benedetto PW, Friberg G, Deng H, McCaffery I, Leitch I, Badola S, Chang S, Zhu M, Tolcher A: Phase II study of ganitumab, a fully human anti-type-1 insulin-like growth factor receptor antibody, in patients with metastatic Ewing family tumors or desmoplastic small round cell tumors. J Clin Oncol 2012, 30: 1849–1856. 10.1200/JCO.2011.37.2359CrossRefPubMed

81.

Van Cutsem E, Eng C, Nowara E, Swieboda-Sadlej A, Tebbutt N, Mitchell EP, Davidenko I, Stephenson J, Elez ME, Prenen H, Deng H, Tang R, McCaffery I, Oliner K, Chen L, Gansert JL, Loh E, Smethurst D, Tabernero J: Randomized phase Ib/II trial of rilotumumab or ganitumab with panitumumab versus panitumumab alone in patients with wild-type KRAS metastatic colorectal cancer. Clin Cancer Res 2014, 20: 4240–4250. 10.1158/1078-0432.CCR-13-2752CrossRefPubMed

82.

Pappo AS, Patel SR, Crowley J, Reinke DK, Kuenkele KP, Chawla SP, Toner GC, Maki RG, Meyers PA, Chugh R, Ganjoo KN, Schuetze SM, Juergens H, Leahy MG, Geoerger B, Benjamin RS, Helman LJ, Baker LH: R1507, a monoclonal antibody to the insulin-like growth factor 1 receptor, in patients with recurrent or refractory Ewing sarcoma family of tumors: results of a phase II Sarcoma Alliance for Research through Collaboration study. J Clin Oncol 2011, 29: 4541–4547. 10.1200/JCO.2010.34.0000PubMedCentralCrossRefPubMed

83.

Lin EH, Lenz HJ, Saleh MN, Mackenzie MJ, Knost JA, Pathiraja K, Langdon RB, Yao SL, Lu BD: A randomized, phase II study of the anti-insulin-like growth factor receptor type 1 (IGF-1R) monoclonal antibody robatumumab (SCH 717454) in patients with advanced colorectal cancer. Cancer Med 2014, 29: 4541–4547.

84.

Macaulay VM, Middleton MR, Protheroe AS, Tolcher A, Dieras V, Sessa C, Bahleda R, Blay JY, LoRusso P, Mery-Mignard D, Soria JC: Phase I study of humanized monoclonal antibody AVE1642 directed against the type 1 insulin-like growth factor receptor (IGF-1R), administered in combination with anticancer therapies to patients with advanced solid tumors. Ann Oncol 2013, 24: 784–791. 10.1093/annonc/mds511PubMedCentralCrossRefPubMed

85.

Moreau P, Cavallo F, Leleu X, Hulin C, Amiot M, Descamps G, Facon T, Boccadoro M, Mignard D, Harousseau JL: Phase I study of the anti insulin-like growth factor 1 receptor (IGF-1R) monoclonal antibody, AVE1642, as single agent and in combination with bortezomib in patients with relapsed multiple myeloma. Leukemia 2011, 25: 872–874. 10.1038/leu.2011.4CrossRefPubMed

86.

von Mehren M, Britten CD, Pieslor P, Saville W, Vassos A, Harris S, Galluppi GR, Darif M, Wainberg ZA, Cohen RB, Leong S: A phase 1, open-label, dose-escalation study of BIIB022 (anti-IGF-1R monoclonal antibody) in subjects with relapsed or refractory solid tumors. Invest New Drugs 2014, 32: 518–525. 10.1007/s10637-014-0064-yPubMedCentralCrossRefPubMed

87.

Burtrum D, Zhu Z, Lu D, Anderson DM, Prewett M, Pereira DS, Bassi R, Abdullah R, Hooper AT, Koo H, Jimenez X, Johnson D, Apblett R, Kussie P, Bohlen P, Witte L, Hicklin DJ, Ludwig DL: A fully human monoclonal antibody to the insulin-like growth factor I receptor blocks ligand-dependent signaling and inhibits human tumor growth in vivo. Cancer Res 2003, 63: 8912–8921.PubMed

88.

Cohen BD, Baker DA, Soderstrom C, Tkalcevic G, Rossi AM, Miller PE, Tengowski MW, Wang F, Gualberto A, Beebe JS, Moyer JD: Combination therapy enhances the inhibition of tumor growth with the fully human anti-type 1 insulin-like growth factor receptor monoclonal antibody CP-751,871. Clin Cancer Res 2005, 11: 2063–2073. 10.1158/1078-0432.CCR-04-1070CrossRefPubMed

89.

Nahta R, Yuan LX, Zhang B, Kobayashi R, Esteva FJ: Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. Cancer Res 2005, 65: 11118–11128. 10.1158/0008-5472.CAN-04-3841CrossRefPubMed

Title: Anti-IGF-1R monoclonal antibody inhibits the carcinogenicity activity of acquired trastuzumab-resistant SKOV3
Authors: Wei Wang
Yan Zhang
Ming Lv
Jiannan Feng
Hui Peng
Jing Geng
Zhou Lin
Tingting Zhou
Xinying Li
Beifen Shen
Yuanfang Ma
Chunxia Qiao
Publication date: 01-12-2014
Publisher: BioMed Central
Published in: Journal of Ovarian Research / Issue 1/2014
Electronic ISSN: 1757-2215
DOI: https://doi.org/10.1186/s13048-014-0103-5

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Anti-IGF-1R monoclonal antibody inhibits the carcinogenicity activity of acquired trastuzumab-resistant SKOV3

Abstract

Background

Methods

Results

Conclusion

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2014

Reliable in vitro studies require appropriate ovarian cancer cell lines

Pregnancy outcome in severe OHSS patients following ascitic/plerural fluid drainage

Increased expression of the leptin receptor in human ovaries affected by endometrioma and detection of high levels of leptin in the ovarian endometriomal fluid

The level of RECQL1 expression is a prognostic factor for epithelial ovarian cancer

Sequence variation among members of the miR-200 microRNA family is correlated with variation in the ability to induce hallmarks of mesenchymal-epithelial transition in ovarian cancer cells

The feasibility and clinical effects of dendritic cell-based immunotherapy targeting synthesized peptides for recurrent ovarian cancer